Synthetic Transcriptional Activators for Cancer Immunotherapy

用于癌症免疫治疗的合成转录激活剂

基本信息

项目摘要

Cancer immunotherapy is a promising approach to treat cancer by activating a patient’s immune system against tumor cells and even providing long-term remission. These clinical benefits have led to recent FDA approvals for immune-checkpoint blockade (ICB), adoptive cell transfer (ACT), and molecular vaccine technologies, and have also motivated substantial commercial investments for their continued development. Nonetheless, these therapies are also associated with nonselective immunogenicity—which limits efficacy and harms healthy tissue. For these treatments to reach their full promise, new strategies are desperately needed to enhance immunotherapy responses while also minimizing off-target effects. One key challenge with developing immunotherapies is achieving robust anti-tumor immune responses. Strategies to promote responses include administering peptide or DNA-encoded T-cell antigens, designed to expand T-cell populations against tumor cells. These vaccines have demonstrated a potential to activate T cells, but often provide limited efficacy due to immune evasion by tumor cells. Recently, engineered transcription factor (ETF) proteins were shown to induce protein expression of latent HIV-infected cell reservoirs by targeting the HIV-1 promoter. Inspired by this approach, we envisioned developing new ETF proteins that induce expression of tumor antigens and, in turn, facilitate immune recognition of cancer cells. Although CRISPR technologies are also used for gene activation, therapeutic applications remain limited due to insufficient safety and intracellular delivery properties. Our overarching goal in this proposal is to demonstrate using an ETF to induce expression of tumor antigens in vitro. Over time, we will establish the efficacy of ETFs, which will guide designs of future in vivo experiments (not included in this proposal) and future grant applications. We will begin these studies by developing ETF activators that induce expression of antigenic proteins associated with human papilloma virus (HPV)-18, which is associated with cervical carcinoma. We selected HPV-18 because it is an ideal starting point for developing ETFs in our group for several reasons. One reason is that the Upstream Regulatory Region (URR) and reporter cell line (HeLa) are well-characterized. Another reason is that these studies build upon the prior work with HIV. If successful, we plan to develop additional ETF proteins as a facile approach for enhancing tumor cell immunogenicity in the clinic. We will develop ETFs through the design, preparation, and characterization of ZF building blocks, which we will assemble to recognize promoter region genes that are 18 nucleotides in length. We will also incorporate a ‘transcriptional activator’ to induce protein transcription and translation. We will evaluate ETF-mediated activation by encoding these constructs into a mammalian expression vector, followed by measuring expression of the protein antigen in cancer cells. We will also prepare synthetic ETFs as therapeutic proteins to enable DNA-binding studies and to enhance intracellular delivery properties.
癌症免疫疗法是一种很有前途的治疗癌症的方法,它通过激活患者的免疫系统来对抗 肿瘤细胞,甚至提供长期缓解。这些临床益处导致了最近FDA的批准 用于免疫检查点阻断(ICB)、过继细胞转移(ACT)和分子疫苗技术,以及 也激励了大量的商业投资,以促进它们的持续发展。尽管如此,这些 治疗还与非选择性免疫原性有关--这限制了疗效并损害了健康 组织。为了使这些治疗方法充分发挥作用,迫切需要新的策略来加强 免疫治疗反应,同时将非靶点效应降至最低。开发的一个关键挑战 免疫疗法正在取得强大的抗肿瘤免疫反应。促进回应的战略包括 注射多肽或DNA编码的T细胞抗原,旨在扩大抗肿瘤的T细胞群 细胞。这些疫苗已经显示出激活T细胞的潜力,但由于以下原因,其疗效往往有限 肿瘤细胞的免疫逃避。最近,工程转录因子(ETF)蛋白被证明能诱导 针对HIV-1启动子的潜伏HIV感染细胞库的蛋白质表达。受此启发 方法,我们设想开发新的ETF蛋白来诱导肿瘤抗原的表达,进而, 促进对癌细胞的免疫识别。虽然CRISPR技术也被用于基因激活, 由于安全性和细胞内给药特性的不足,治疗应用仍然有限。 我们在这项提案中的首要目标是演示使用ETF来诱导肿瘤抗原的表达 在试管中。随着时间的推移,我们将建立ETF的有效性,这将指导未来的活体实验设计 (不包括在本提案中)和未来的赠款申请。我们将从开发ETF开始这些研究 诱导人乳头瘤病毒(HPV)-18相关抗原蛋白表达的激活剂, 与宫颈癌有关。我们选择HPV-18是因为它是开发HPV-18的理想起点 ETF出现在我们的组中有几个原因。一个原因是上游监管区(URR)和记者 细胞系(HeLa)的特性良好。另一个原因是,这些研究建立在以前关于艾滋病毒的工作的基础上。如果 成功后,我们计划开发更多的ETF蛋白,作为增强肿瘤细胞的简便方法 临床上的免疫原性。我们将通过ZF的设计、准备和表征来开发ETF 我们将组装它们来识别长度为18个核苷酸的启动子区域基因。 我们还将加入一种‘转录激活剂’来诱导蛋白质转录和翻译。我们会 通过将这些构建物编码到哺乳动物表达载体中来评估ETF介导的激活, 通过测量癌细胞中蛋白质抗原的表达。我们还将准备合成ETF作为 治疗性蛋白质,使DNA结合研究成为可能,并增强细胞内的递送特性。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

IGOR B RONINSON其他文献

IGOR B RONINSON的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('IGOR B RONINSON', 18)}}的其他基金

Synthetic Transcriptional Activators for Cancer Immunotherapy
用于癌症免疫治疗的合成转录激活剂
  • 批准号:
    10868915
  • 财政年份:
    2023
  • 资助金额:
    $ 19.92万
  • 项目类别:
Center for Targeted Therapeutics
靶向治疗中心
  • 批准号:
    10372263
  • 财政年份:
    2014
  • 资助金额:
    $ 19.92万
  • 项目类别:
Center for Targeted Therapeutics
靶向治疗中心
  • 批准号:
    9978871
  • 财政年份:
    2014
  • 资助金额:
    $ 19.92万
  • 项目类别:
Center for Targeted Therapeutics
靶向治疗中心
  • 批准号:
    8885848
  • 财政年份:
    2014
  • 资助金额:
    $ 19.92万
  • 项目类别:
Center for Targeted Therapeutics
靶向治疗中心
  • 批准号:
    10221696
  • 财政年份:
    2014
  • 资助金额:
    $ 19.92万
  • 项目类别:
Admin-Core
管理核心
  • 批准号:
    10624907
  • 财政年份:
    2014
  • 资助金额:
    $ 19.92万
  • 项目类别:
Admin-Core
管理核心
  • 批准号:
    10403529
  • 财政年份:
    2014
  • 资助金额:
    $ 19.92万
  • 项目类别:
Center for Targeted Therapeutics
靶向治疗中心
  • 批准号:
    9794379
  • 财政年份:
    2014
  • 资助金额:
    $ 19.92万
  • 项目类别:
Admin-Core
管理核心
  • 批准号:
    10221715
  • 财政年份:
    2014
  • 资助金额:
    $ 19.92万
  • 项目类别:
METABOLIC ANALYSIS INSTRUMENTATION TO ENHANCE TARGETED THERAPEUTICS STUDIES
代谢分析仪器可增强靶向治疗研究
  • 批准号:
    10400414
  • 财政年份:
    2014
  • 资助金额:
    $ 19.92万
  • 项目类别:

相似国自然基金

Neo-antigens暴露对肾移植术后体液性排斥反应的影响及其机制研究
  • 批准号:
    2022J011295
  • 批准年份:
    2022
  • 资助金额:
    10.0 万元
  • 项目类别:
    省市级项目
结核分枝杆菌持续感染期抗原(latency antigens)的重组BCG疫苗研究
  • 批准号:
    30801055
  • 批准年份:
    2008
  • 资助金额:
    19.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

Bovine herpesvirus 4 as a vaccine platform for African swine fever virus antigens in pigs
牛疱疹病毒 4 作为猪非洲猪瘟病毒抗原的疫苗平台
  • 批准号:
    BB/Y006224/1
  • 财政年份:
    2024
  • 资助金额:
    $ 19.92万
  • 项目类别:
    Research Grant
A novel vaccine approach combining mosquito salivary antigens and viral antigens to protect against Zika, chikungunya and other arboviral infections.
一种结合蚊子唾液抗原和病毒抗原的新型疫苗方法,可预防寨卡病毒、基孔肯雅热和其他虫媒病毒感染。
  • 批准号:
    10083718
  • 财政年份:
    2023
  • 资助金额:
    $ 19.92万
  • 项目类别:
    Small Business Research Initiative
Uncovering tumor specific antigens and vulnerabilities in ETP-acute lymphoblastic leukemia
揭示 ETP-急性淋巴细胞白血病的肿瘤特异性抗原和脆弱性
  • 批准号:
    480030
  • 财政年份:
    2023
  • 资助金额:
    $ 19.92万
  • 项目类别:
    Operating Grants
Regulation of B cell responses to vaccines by long-term retention of antigens in germinal centres
通过在生发中心长期保留抗原来调节 B 细胞对疫苗的反应
  • 批准号:
    MR/X009254/1
  • 财政年份:
    2023
  • 资助金额:
    $ 19.92万
  • 项目类别:
    Research Grant
Adaptive Discrimination of Risk of Antigens in Immune Memory Dynamics
免疫记忆动态中抗原风险的适应性辨别
  • 批准号:
    22KJ1758
  • 财政年份:
    2023
  • 资助金额:
    $ 19.92万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
22-ICRAD Call 2 - Improving the diagnosis of tuberculosis in domestic ruminants through the use of new antigens and test platforms
22-ICRAD 呼吁 2 - 通过使用新抗原和测试平台改善家养反刍动物结核病的诊断
  • 批准号:
    BB/Y000927/1
  • 财政年份:
    2023
  • 资助金额:
    $ 19.92万
  • 项目类别:
    Research Grant
Protective immunity elicited by distinct polysaccharide antigens of classical and hypervirulent Klebsiella
经典和高毒力克雷伯氏菌的不同多糖抗原引发的保护性免疫
  • 批准号:
    10795212
  • 财政年份:
    2023
  • 资助金额:
    $ 19.92万
  • 项目类别:
Integrative proteome analysis to harness humoral immune response against tumor antigens
综合蛋白质组分析利用针对肿瘤抗原的体液免疫反应
  • 批准号:
    23K18249
  • 财政年份:
    2023
  • 资助金额:
    $ 19.92万
  • 项目类别:
    Grant-in-Aid for Challenging Research (Exploratory)
Functionally distinct human CD4 T cell responses to novel evolutionarily selected M. tuberculosis antigens
功能独特的人类 CD4 T 细胞对新型进化选择的结核分枝杆菌抗原的反应
  • 批准号:
    10735075
  • 财政年份:
    2023
  • 资助金额:
    $ 19.92万
  • 项目类别:
Targeting T3SA proteins as protective antigens against Yersinia
将 T3SA 蛋白作为针对耶尔森氏菌的保护性抗原
  • 批准号:
    10645989
  • 财政年份:
    2023
  • 资助金额:
    $ 19.92万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了